Phase I/II vaccine study targeting novel HLA-A2-restricted CTL epitopes in combination with poly-ICLC in patients with recurrent malignant glioma. ASCO 2011.

Abstract

Hodgkin’s Lymphoma Cell Lines Have Up-regulated IL-3 Receptor α (IL-3Rα) Expression and are Sensitive to SL-401, an IL-3Rα-Targeted Drug. ASH 2011.

Abstract | Poster

The IL-3Rα-Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid Dendritic Cell Neoplasm Cells. ASH 2011.

Abstract | Poster

A pilot study of peptide-based vaccines in combination with poly ICLC in patients with WHO grade 2 low-grade glioma. AACR 2012.

Abstract

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML. ASH 2012.

Abstract | Poster

SL-101, A Novel Monoclonal Antibody-Conjugate That Targets Interleukin-3 Receptor Alpha (CD123), Possesses Preclinical Anti-Tumor Activity Against Hodgkin’s Lymphoma. ASH 2012.

Abstract | Poster